Today we have Eagle Pharmaceuticals President & CEO, Scott Tarriff and Adrian Hepner, M.D., PhD, EVP Clinical Research, Regulatory & Medical Affairs. Eagle Pharmaceuticals recently announced that the FDA granted Fast Track Designation to their product, RYANODEX, for treatment of exertional heat stroke. The Fast Track Designation highlights a serious, unmet medical need that exists for patients with exertional heat stroke. Scott and Adrian join us to discuss the FDA designation and RYANODEX.